Factors Impacting the Prevalence of MDR Bacteria

August 17, 2022 updated by: Zahraa Najah Mohsin, Kufa University

Evaluation of the Prevalence and Antibiotic Susceptibility Pattern of Multidrug Resistance Bacteria and Its Association With Patients' Predictive Factors

  1. To determine the prevalence of multidrug resistance bacteria in patient with different infections
  2. To evaluate patients' predictive risk factors of antimicrobial resistance
  3. To assess the association between patients' factors and prevalence of MDR bacteria

Study Overview

Status

Completed

Conditions

Detailed Description

Antimicrobial resistance is one of the most critical public health issue in this century . WHO declared antimicrobial resistance as one of the top ten global health threats that impend the effective management and prevention of evolving infections .

Antimicrobial resistance nowadays poses a big challenge because of the emerging of resistance to the antibiotics that previously effective and development of multidrug resistance infections with subsequent increase in morbidity, mortality and financial loss .

In spite of WHO health strategies that taken to face multidrug resistance problem, the burden of antimicrobial resistance in Europe is compared with combined burden of influenza and HIVS .while in USA the estimated antibiotics resistance infections is 2.8 millions and the related deaths exceeded 35,000 every year and expected to reach to ten million deaths with collective cost of 100 trillion USD annually in 2050 .

Numerous studies reported that self-medications, improper prescription, overuse of antibiotics, deficiency of antibiotics susceptibility test and limited knowledge and attitude of population towards antibiotics are the main factors that lead to antibiotics efficacy being reduced with long hospital stay. Other studies stated that the predictive indicators of MDR tragedy are age, gender, comorbidities, previous hospital stay or antibiotic use .

In low and middle income countries like IRAQ there is a difficulty in estimation the scope of antibiotics resistance problem and its evolving over time due to the lack of surveillance, besides alarmingly excessive antibiotics consumption added other challenges and urged us to aim this study .

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iraq
      • Najaf, Iraq
        • Faculty of pharmacy /kufa university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients hospitalized with bacterial infection and screened for MDR bacteria in AL-Zahraa teaching hospital or AL-Sader medical city

Description

Inclusion Criteria:

  • patients who were screened for MDR bacteria
  • patients who accepted to participate in the study

Exclusion Criteria:

  • patients with no growth media
  • patients who cannot communicated

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of multidrug resistance bacteria in isolated patient specimen
Time Frame: based line value (zero months)
proportion of MDR bacteria that detected in isolated specimen
based line value (zero months)
Association of patient's factors with prevalence of multidrug resistance Bacteria.
Time Frame: based line value (zero months)
exploring the association between patient's factors and the prevalence of MDR bacteria by multivariate analysis
based line value (zero months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Methicillin resistance staph. Aureus (MERSA)
Time Frame: based line value (zero months)
proportion of participants with MERSA bacteria that detected in isolated specimen
based line value (zero months)
Prevalence of vancomycin (-resistant Enterococci VRE)
Time Frame: based line value (zero months)
proportion of participants with VRE bacteria that detected in isolated specimen
based line value (zero months)
Prevalence of extended spectrum β lactamase producers (ESBL)
Time Frame: based line value (zero months)
proportion of participants with ESBL bacteria that detected in isolated specimen
based line value (zero months)
Knowledge, attitude and practice (KAP) toward antibiotic use
Time Frame: based line value (zero months)
the score indicator of KAP through a module of KAP survey by 20 categorized questions the knowledge is individual understanding about antibiotic resistance the attitude is the perceptions and beliefs that respondents (+),(-) perceive towards antibiotic resistance the practice is the observable actions of individual towards antibiotic use
based line value (zero months)
Risk factors for antibiotic resistance
Time Frame: based line value (zero months)
asses patient's predictive factors and their role in prevalence of multidrug resistance bacteria
based line value (zero months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kufa University

Investigators

  • Study Director: Hayder Asaad, assist. prof, college of pharmacy kufa university

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2022

Primary Completion (Actual)

May 1, 2022

Study Completion (Actual)

May 15, 2022

Study Registration Dates

First Submitted

October 18, 2021

First Submitted That Met QC Criteria

October 18, 2021

First Posted (Actual)

October 29, 2021

Study Record Updates

Last Update Posted (Actual)

August 18, 2022

Last Update Submitted That Met QC Criteria

August 17, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • MDR and predictive factors

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multi-antibiotic Resistance

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe